Amicogen, Inc.

As of March 31, 2026, Amicogen, Inc. carries a market capitalization of 114.49B, placing it among publicly traded companies globally. Its enterprise value stands at 169.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Amicogen, Inc. has 70.45M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 2.13, and the price-to-book ratio stands at 0.86.

These figures are as of March 31, 2026. The EV/Sales ratio of 3.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 169.90B versus a market cap of 114.49B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Amicogen, Inc. maintains a current ratio of 1.07, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 46.70, indicating elevated leverage, while an interest coverage ratio of -0.78 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Amicogen, Inc. posted a negative return on equity (ROE) of -3.64, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.86, reflecting losses generated across the asset base. The company generates approximately 192.64M in revenue per employee across its workforce of 225.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.61 indicates how many times Amicogen, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Amicogen, Inc. recorded 1.24B in income tax expense. The company reported a pretax loss of -3.96B and -4.54B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Amicogen, Inc.'s stock has declined approximately 71.70% over the past 52 weeks. The 50-day moving average sits at 965.84, while the 200-day moving average is 1,392.16.

Over the twelve months ended March 31, 2026, Amicogen, Inc. generated 43.44B in revenue and converted that into -4.54B in net income, yielding earnings per share of -90.95. EBITDA reached -6.02B, while operating income came in at -15.95B.

As of March 31, 2026, Amicogen, Inc. holds 7.81B in cash and equivalents against 62.28B in total debt, resulting in a net debt position of 54.69B. Total book value stands at 132.40B, with working capital of 2.88B providing operational flexibility.

Amicogen, Inc. produced -47.59B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -1.39B in capital expenditures, free cash flow totaled -48.98B - equivalent to -859.91 per share.

Over the twelve months ended March 31, 2026, Amicogen, Inc. posted a gross margin of 15.27, reflecting its pricing power and cost economics. The operating margin of -36.72 and net profit margin of -10.45 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -52.73: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Amicogen, Inc. shareholders.

Amicogen, Inc.'s most recent stock split took place on December 13, 2023 with a 1:2 split ratio.

As of March 31, 2026, Amicogen, Inc. has an Altman Z-Score of 0.48, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.